Skip to content

About
Mission
Technology
- Technology Overview
- Annamycin
- WP1066
- WP1122
- WP1732
- WP1234
- WP1220
- Expanded Access
Pipeline
Partnerships
Science
News
- Press Releases
- Media Archive
Investors

Main Menu

Moleculin Biotech

A clinical-stage pharmaceutical company focused on the treatment of highly resistant tumors.

Shareholder Letter 2020
Pancreatic Cancer
Acute Myeloid Leukemia
Brain Tumors
Skin Cancer

Home
Shareholder Letter 2020
Pancreatic Cancer
Acute Myeloid Leukemia
Brain Tumors
Skin Cancer
About Us
Technology
- Technology Overview
- Annamycin
- WP1066
- WP1122
- WP1732
- WP1234
- WP1220
Pipeline
Partnerships
Science
News
Investors
Contact Us

Development Pipeline

Robust pipeline with potentially disruptive technologies
focused on the treatment of highly resistant cancers.

LEARN MORE ABOUT OUR TECHNOLOGIES

Development Pipeline

Internally Funded

Externally Funded

Potential 2020 Value Inflection Points

Development Pipeline

Internally Funded

Externally Funded

Potential Value Inflection Points

Contact Us

Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX, 77007

info@moleculin.com
(713) 300-5160

Follow Us

Find us on:

Facebook Twitter

Email Alerts

Name
Email
CAPTCHA

Copyright 2019 Moleculin Biotech, Inc. All Rights Reserved.